Psilera Greenlit for Phase 2 of NIH Grant for Alcohol Use Disorder

Psilera Inc. has been approved to advance to Phase 2 of a National Institutes of Health (NIH)-funded study investigating the treatment of alcohol use disorder. The research will explore the potential of psychedelic compounds in addressing addictive disorders.

The project aims to examine the effects of psilocybin-like compounds on neuroplasticity and their potential benefits in managing alcohol dependence. Promising outcomes from the initial phase have paved the way for this next stage of investigation.

Psilera Inc. is a biopharmaceutical company dedicated to pioneering next-generation psychedelics and neuroplastogens for mental health and neurological conditions. The company focuses on advancing scientific understanding and clinical application of these therapeutic agents.

This research is part of a broader trend of increasing scientific and governmental interest in the therapeutic potential of psychedelic-assisted treatments for various health conditions. The progression of such studies could lead to new treatment paradigms.